Design and experimental validation of the action of small molecule-based inhibitors of the FADD protein

Nikita V. Ivanisenko, L. Hillert, В. А. Иванисенко, I. N. LavrikVavilov 2016 · DOI

TL;DR

Researchers combined high-throughput virtual screening with cellular assays to identify small molecules that inhibit FADD, a critical adaptor protein in programmed cell death (apoptosis). They identified a lead compound, FADDin B, which shows a modest ability to block apoptosis without being toxic to cells, providing a structural blueprint for future neuroprotective and anti-cancer drugs.

What Problem Does This Paper Address?

Apoptosis, or programmed cell death, is a fundamental biological process. When it goes haywire, it leads to disaster: too much cell death causes neurodegenerative diseases, while too little leads to cancer.

At the heart of the "extrinsic" death pathway is a molecular machine called the DISC (Death-Inducing Signaling Complex). The protein FADD (Fas-Associated Death Domain) acts as the essential glue of this complex. It has two ends: one that anchors to the cell's "death receptors" (like CD95) and another (the DED domain) that recruits the "executioner" enzymes (caspases).

The challenge is that protein-protein interactions (PPIs) like those involving FADD are notoriously difficult to target with drugs because they lack the deep, well-defined pockets found in enzymes. This paper seeks to find small molecules that can wedge themselves into FADD's DED domain to prevent it from triggering the death cascade.

Methods

The authors employed a "rational design" workflow:

  1. In Silico Screening: Using the Glide software (Schrödinger, Inc.), they performed molecular docking. Crucially, they didn't just use one static image of FADD. They used an ensemble of 25 different shapes (conformations) of the protein determined by NMR spectroscopy (PDB ID: 2GF5).
  2. Targeting a Specific Pocket: They focused on a hydrophobic pocket near the Y25 amino acid residue, which is known to be vital for FADD's ability to cluster and activate caspases.
  3. Experimental Validation: They took the top six candidates (named FADDin A through F) and tested them on Jurkat T-cells. They induced cell death using a CD95 ligand and measured cell viability by detecting ATP levels—since dead cells stop producing ATP, it serves as a reliable "life meter."

Datasets

  • ZINC NCI Diversity Set: A library of ~1,900 diverse chemical compounds used for the initial "standard precision" (SP) screening.
  • ZINC Database: A massive library of over 3.5 million commercially available compounds used for the expanded "extra precision" (XP) virtual screening.
  • PDB 2GF5: The NMR-derived structural ensemble of the full-length FADD protein.

Key Insights and Ideas

  • Conformational Matters: The study highlights that protein flexibility is key. Out of 25 possible shapes for FADD, only a few (specifically Conformation #13) were found to be optimal targets for the most effective inhibitors. This suggests that FADD might only be "druggable" in specific states.
  • The Toxicity Trap: One of the candidates, FADDin A, initially looked promising in simulations but turned out to be highly toxic to cells on its own. This underscores the necessity of following up computational "hits" with wet-lab "bits."
  • A New "Druggable" Site: By identifying the hydrophobic pocket near residue Y25, the authors have mapped out a specific coordinate on the FADD protein that can be targeted by small molecules, moving beyond the idea of PPIs as "undruggable" flat surfaces.

Key Results

  • FADDin B as the Lead: Compound FADDin B (ZINC 48159387) was the standout. At a concentration of 20 µM, it showed no non-specific toxicity (it didn't kill cells on its own) and provided a detectable inhibitory effect against CD95-induced apoptosis at the 6-hour mark.
  • Quantitative Findings: In the presence of FADDin B, ATP levels in cells treated with death ligands were higher than in untreated controls, indicating more cells survived the "death signal."
  • Structural Correlation: The most active inhibitor (FADDin B) docked best with FADD Conformation #13, suggesting this specific structural state is the one involved in the early stages of DISC formation.

Limitations and Future Work

The authors are candid about the fact that the inhibitory effect of FADDin B, while present, was "not very significant." The protection it offered was modest and seemed to wear off by the 22-hour mark, likely because the compound isn't potent enough to permanently block the massive signaling cascade of the DISC.

Future directions include: * Chemical Optimization: Using FADDin B as a "scaffold" and modifying its structure to increase its binding affinity (making it "stickier" to the protein). * Alternative Sites: Exploring other pockets on the FADD protein that might offer more robust inhibition. * SAR Studies: Conducting formal Structure-Activity Relationship (SAR) studies to understand exactly which parts of the molecule are doing the heavy lifting.

Summary updated

Abstract

CD95 is one of the best studied members of the death receptor family. Activation of CD95 leads to the induction of the cell death programme, apoptosis, via formation of the death-inducing signaling complex (DISC). FA DD is a key adaptor protein for the formation of the C D95 DISC and activation of caspase-8 in the receptor complex. FA DD comprises the death domain and the death effector domain (DED). The death domain is essential for the interactions of FA DD with CD95, while DED is necessary for the recruitment of procaspase-8, -10 and the protein c-FLIP into the DISC. The search for the inhibitors that would block the interactions of FA DD with the other core proteins of the DISC is essential for the studies of the structure and function of this complex, investigation of the apoptosis mechanisms and development of new treatments for neurodegenerative diseases. In the course of this work, the screening for small inhibitors in silico that selectively interact with DED has been performed. For this purpose, the molecular modeling of the protein complexes and virtual screening of the potential inhibitors of FA DD has been performed. In addition, a new technology to test the activity of these inhibitors has been developed. The computational and experimental analysis performed allowed us to characterize the optimal conformation of the FA DD protein for the design of the small molecules that can bind in the region of amino acid residue Y25. We presume that further optimization of the structures of chemical compounds that can bind with the hydrophobic pocket next to the residue Y25 of FA DD will allow for the creation of the new perspective inhibitors of the programmed cell death.
BibTeX
@inproceedings{ivanisenko2016design,
  author = {Nikita V. Ivanisenko and L. Hillert and В. А. Иванисенко and I. N. Lavrik},
  title = {{Design and experimental validation of the action of small molecule-based inhibitors of the FADD protein}},
  booktitle = {Vavilov},
  year = {2016},
  doi = {10.18699/vj15.084},
}
Figure